Safety and tolerability of CTH120, first-in-human phase I study encompassing three parts: Single and Multiple Ascending doses and potential Food Interaction

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- First administration to humans

Sponsor

Connecta Therapeutics S.L.

Enrolment target

68

Start

17 May 2023

Age 18 Years to any · Sex: All

• —

  Spain